Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 941-628-3 | CAS number: 1263184-87-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 14 May 2014 to 14 Oct 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 14 May 2014 to 14 Oct 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- Adopted 22nd January 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.3500 (Preliminary Developmental Toxicity Screen)
- Version / remarks:
- July 2000
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:WI(Han)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: (P) 8 to 9 weeks
- Weight at study initiation: (P) Males: 269 to 325 g; Females: 175 to 214 g
- Fasting period before study: No
- Housing: Animals were housed in groups of five, by sex, until pairing and for males post-pairing. For pairing, one male and one female from the same group were housed together in grid-floor cages suspended over paper-lined trays. On confirmation of mating, the males were returned to the group cages and the mated females were housed individually and subsequently with their litter, in solid floor cages with bedding material provided.
- Diet: pelleted rodent diet, ad libitum
- Water: Tap water, ad libitum
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 22
- Humidity (%): 45 to 63
- Air changes (per hr): Not specified
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES:
14 May 2014 to 14 Oct 2014 - Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 1% (w/v)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was formulated at approximately weekly intervals (within the period of known stability), for each group separately, as a suspension in 1 % (w/v) aqueous carboxymethylcellulose. A weighed quantity of test item was added to a beaker and vehicle was gradually added whilst stirring. The suspension was removed from the stirrer and made up to final volume/weight with more vehicle and mixed with a laboratory homogeniser. For the formulations prepared for use on the first dosing occasion only, solid black flecks were visible after homogenisation and therefore the formulations were placed in an ultrasonic bath for up to 114 minutes, to ensure complete dispersion and homogeneity. After preparation, all formulations were dispensed into daily aliquots which were stored refrigerated. Formulations were stirred from at least 15 minutes before the start of dosing until completion of dosing to ensure thorough re-suspension and homogeneity.
VEHICLE
- Concentration in vehicle: 0 (control), 10, 30 and 100 mg/mL, corresponds to 0, 100, 300 and 1000 mg/kg bw/day test substance in dose formulation
- Amount of vehicle: 10 mL/kg bw - Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: up to 14 days
- Proof of pregnancy: sperm in vaginal smear referred to as Day 0 of pregnancy
- After 14 days of unsuccessful pairing replacement of first male by another male with proven fertility.
- Further matings after two unsuccessful attempts: no
- After successful mating each pregnant female was caged individually - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentrations of the test substance in formulations used on the first and last days of dosing have been determined using a validated method of analysis. The concentrations and homogeneity of the test substance in the formulations used on the first dosing occasion were determined from the analysis of triplicate samples from the top, middle and bottom of each formulation. The achieved concentrations of the test substance in the formulations used on the last day of dosing were determined from the analysis of triplicate samples from the middle of each formulation.
Samples from vehicle used to dose control animals on these occasions were analysed to confirm the absence of test substance. The formulations were considered to have been accurately prepared and homogeneous (where assessed) if the measured concentrations of the test substance were within ± 10% of their nominal values with coefficients of variation no greater than 5%. - Duration of treatment / exposure:
- Males were dosed once daily for 14 days before and during pairing and until the day before necropsy.
Females were dosed once daily for 14 days before pairing, during pairing and until Day 3 of lactation. Animals that were in midparturition at the time of dosing were not dosed on that day. - Frequency of treatment:
- Once daily
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Remarks:
- Group 2
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Remarks:
- Group 3
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- Group 4
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were selected by the Sponsor after examining existing toxicity data from a 28 day toxicity study.
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS:
- Time schedule: daily for clinical signs of toxicity or changes in behaviour and appearance and each animal. Furthermore, twice daily for mortality and morbidity.
DETAILED CLINICAL OBSERVATIONS:
- Time schedule: Once each week
BODY WEIGHT:
- Time schedule for examinations: Male body weights were recorded on the first day of dosing and at weekly intervals throughout the study. Female body weights were recorded on the first day of dosing and then at weekly intervals until the day of mating. Females were also weighed on Days 0, 7, 14 and 20 of gestation and on Days 0 (where required for dose volume calculations), 1 and 4 of lactation.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/animal/day: Yes
OTHER:
The females were allowed to rear their offspring to Day 4 of lactation. Abnormalities of nesting or nursing behaviour were recorded. - Oestrous cyclicity (parental animals):
- During the pairing period the estrous cycle was determined by the type of cells present in the vaginal smears taken.
- Sperm parameters (parental animals):
- Parameters examined in P male parental generations: testis weight, epididymis weight
- Litter observations:
- PARAMETERS EXAMINED
The following parameters were examined in F1 offspring: number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, weight gain, physical or behavioural abnormalities
GROSS EXAMINATION OF DEAD PUPS:
yes, for external and internal abnormalities - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals were sacrificed after the females had littered and been necropsied
- Maternal animals: All surviving animals were sacrificed on Day 4 of lactation
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the thoracic, and abdominal viscera. For females, the uterus was examined and the number of implantation scars recorded on Day 4 of lactation.
HISTOPATHOLOGY / ORGAN WEIGHTS
The tissues indicated in Table 1 in ‘Any other information on materials and methods incl. tables’ were prepared for microscopic examination and weighed, respectively. - Postmortem examinations (offspring):
- SACRIFICE
- The F1 offspring were sacrificed at 4 days of age.
- These animals were subjected to postmortem examinations (macroscopic examination) as follows:
GROSS NECROPSY
- Gross necropsy consisted of external and internal examinations including the thoracic and abdominal viscera. - Statistics:
- Data were processed to give group mean values and standard deviations, where appropriate. Where the data allowed, the following methods were used for statistical analysis comparing Groups 2, 3 and 4 against Group 1.
General Approach: All statistical tests were two-sided with minimum significance levels of 5% and 1%. Non-parametric statistics were not routinely conducted. When used, Dunnett’s test was conducted regardless of the outcome of the analysis of variance (ANOVA) or analysis of covariance (ANCOVA). After examining for any outliers, if the variances were clearly heterogeneous, transformations were used in an attempt to stabilise the variances.
For Quantitative Data: Body weight, food intake, cumulative body weight gain from the start of dosing (throughout gestation and lactation), pup body weights, cumulative pup body weight gain, litter size, gestation length and total litter weight were analysed using ANOVA. Parental organ weights were analysed using ANOVA for the absolute weights and by analysis of covariance (ANCOVA) using terminal kill body weight as covariate.
For Percentages: Pup survival, pup sex ratios and litter based mean percentages were analysed using a parametric ANOVA, following a double arcsine transformation.
Dunnett’s test: For all of the parameters evaluated initially by ANOVA or ANCOVA, Dunnett’s test was used to compare the control and treated groups, based on the error mean square in the ANOVA or ANCOVA. The Dunnett’s test was performed for all continuous data parameters, regardless of whether the initial ANOVA or ANCOVA was statistically significant, and statistical flags are presented in the tables of results in the final report. - Reproductive indices:
- See Table 2 in 'Any other information on materials and methods incl. tables'.
- Offspring viability indices:
- See Table 2 in 'Any other information on materials and methods incl. tables'.
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test item-related clinical observations.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One female animal, administered 1000 mg/kg/day, was killed on Day 0 of lactation due to poor clinical condition within 102 minutes of dosing. Littering had been completed successfully and 13 live pups born. However, observations post dosing included decreased activity, prostrate posture and slow breathing indicative of a possible mis-dose although there were no macroscopic necropsy findings to confirm this. This death was an isolated incidence and, in the absence of other deaths or clinical signs of toxicity at 1000 mg/kg/day in this study or in a 28-day toxicity study, was considered to be incidental and not related to treatment with the test item.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Throughout the dosing period, males given 1000 mg/kg/day had reduced body weight gains (p<0.01) compared with Controls (-29 %). Males given 300 mg/kg/day had lower body weight gains (-9 %) throughout the dosing period compared with Controls, although the difference was not statistically significant. There was no effect on body weight or body weight gains for males at 100 mg/kg/day or for females during pre-pairing, gestation or lactation, at any dose level.
See Tables 1 to 4 in ‘Any other information on results incl. tables’. - Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment-related microscopic changes were found in the liver of males and females and in the thyroid of males. These changes are described below. The spectrum of all other microscopic findings was consistent with changes encountered in rats of this age kept under laboratory conditions and none was considered to be treatment-related
Liver: Hepatocellular hypertrophy (minimal) was present in all males and 2/10 females given 1000 mg/kg/day and in 2/10 males given 300 mg/kg/day. The incidence of the treatment related change was dose-related in males and accounted for the observed dose-related increases in liver weight in both sexes.
Thyroids: There was an increased incidence of thyroid follicular hypertrophy (minimal) in males given 300 mg/kg/day or 1000 mg/kg/day when compared with males from the Control group. This increased incidence was considered to be treatment-related. Although the incidence of follicular cell hypertrophy in males given 100 mg/kg/day was greater than that found in the concurrent Controls, the finding was considered to be within the spectrum of change encountered in male rats of this strain kept under laboratory conditions and therefore incidental to treatment. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not examined
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Description (incidence and severity):
- Fertility and mating performance were unaffected by the test substance, all animals mated within four days of pairing, with no effects on the pregnancy parameters. There was no effect of treatment on the mean duration of gestation, with all pregnant females giving birth to live litters.
See Tables 6 and 7 in ‘Any other information on results incl. tables’. - Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Systemic toxicity
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- body weight and weight gain
- organ weights and organ / body weight ratios
- histopathology: non-neoplastic
- Dose descriptor:
- NOAEL
- Remarks:
- Systemic toxicity
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- organ weights and organ / body weight ratios
- histopathology: non-neoplastic
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Reproductive toxicity
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- See Table 5 in ‘Any other information on results incl. tables’.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related macroscopic findings.
- Histopathological findings:
- not examined
- Other effects:
- not examined
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Developmental toxicity
- Generation:
- F1
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- In this GLP compliant OECD 421 study, a reproduction/ developmental toxicity screening was performed on male and female Crl:WI(Han) mice. The following NOAELs were found:
- Systemic toxicity: 100 mg/kg bw/day based on reduced body weight, increased liver weights and minimal hepatocellular hypertrophy in males.
- Reproductive toxicity: > 1000 mg/kg bw/day - Executive summary:
In this GLP compliant OECD 421 study, a reproduction/ developmental toxicity screening was performed. Forty male and 40 female rats of the Crl:WI(Han) strain were allocated to the study. Groups of 10 males and 10 females were dosed with 0 (vehicle), 100, 300 or 1000 mg/kg/day test substance, once daily, by oral gavage at a dose volume of 10 mL/kg body weight using 1% aqueous carboxymethylcellulose as vehicle. Males were dosed for 14 days before and during pairing and until the day before necropsy (47 days) and the females were dosed for 14 days before pairing, during pairing and then until Day 3 of lactation (approximately 42 days). All animals were examined for effects on general condition, body weight and food intake. During the pairing period vaginal smears were taken daily until sperm were found in the smear. The females were allowed to litter and rear their offspring to Day 4 of age. A macroscopic necropsy was performed on all parental animals and F1 generation pups. For the parental males and females a selection of organs were weighed, fixed and examined microscopically.
There were no deaths considered to be related to treatment with the test item and no test-item related clinical signs. Throughout the dosing period, males given 300 mg/kg/day or 1000 mg/kg/day showed reduced body weight gain, compared with Controls. There was no effect on body weight or body weight gain for females at any dose level or for males given 100 mg/kg/day. There was no effect on food intake for males or females at any dose level. Fertility and mating performance were unaffected by treatment with the test substance and there were no effects on pregnancy parameters. Males given 300 mg/kg/day and both sexes given 1000 mg/kg/day showed increased liver weights adjusted for body weight. Minimal hepatocellular hypertrophy was noted in males given 300 mg/kg/day and in both sexes given 1000 mg/kg/day. Minimal thyroid follicular hypertrophy was also seen in males given 300 or 1000 mg/kg/day. There was no effect of maternal treatment with the test substance on pup body weights to Day 4 of age. Pup survival was similar across all groups including the Controls.
In conclusion, the test substance administered once daily by oral gavage to male and female rats at doses of 0, 100, 300 or 1000 mg/kg/day was well tolerated at all dose levels. The No Observed Adverse Effect Level (NOAEL) for male and female reproductive performance was 1000 mg/kg/day. The NOAEL for parental toxicity was 100 mg/kg/day. Reduced body weight and thyroid follicular hypertrophy were observed at the higher dose levels in males only. Increased liver weight in association with minimal hepatocellular hypertrophy was observed at 300 (males only) and 1000 mg/kg/day, in both sexes with males being more severely affected than females.
Formulation analysis
Test item formulations from the first preparation occasion and those used on the last day of dosing were considered to have been accurately prepared and homogeneous (where assessed) since the measured concentrations of the test substance were within 5 % of their nominal values with coefficients of variation no greater than 1.3 % which fulfilled the acceptance criteria (± 10 % and ≤ 5 % for accuracy and homogeneity, respectively).
No test substance was detected in vehicle used to dose Control animals.
Table 1. Body Weights (g) - P Generation Males - Group Mean Values
Sex: Male |
Body Weight (Week Number) |
|||||||
Group |
0# |
1# |
2# |
3# |
4# |
5# |
6# |
|
Group: 1 Control 0 mg/kg/day |
Mean |
294.0 |
320.0 |
340.7 |
353.6 |
365.0 |
380.0 |
392.3 |
SD |
14.0 |
16.1 |
17.9 |
16.6 |
18.9 |
19.6 |
16.6 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Group: 2 100 mg/kg/day |
Mean |
295.6 |
324.9 |
348.7 |
354.8 |
377.8 |
390.9 |
402.5 |
SD |
17.8 |
20.6 |
21.7 |
16.2 |
22.8 |
21.0 |
22.7 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Group: 3 300 mg/kg/day |
Mean |
288.4 |
308.6 |
328.6 |
341.3 |
352.6 |
368.4 |
377.9 |
SD |
18.5 |
21.6 |
25.9 |
26.3 |
24.6 |
31.1 |
28.6 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Group: 4 1000 mg/kg/day |
Mean |
291.5 |
301.1 |
321.4 |
335.1 |
345.8 |
352.0 d1 |
361.5 d1 |
SD |
15.1 |
23.5 |
23.8 |
24.1 |
25.4 |
25.4 |
26.0 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
# [Statistically Analysed]
1 [d - Test: Dunnett 2 Sided p < 0.05]
Table 2. Body Weights (g) - P Generation Females - Pre-Pairing - Group Mean Values
Sex: Female |
Body Weight (Week Number) |
|||
Group |
0# |
1# |
2# |
|
Group: 1 Control 0 mg/kg/day |
Mean |
189.4 |
198.2 |
209.0 |
SD |
7.1 |
7.1 |
8.5 |
|
N |
10 |
10 |
10 |
|
Group: 2 100 mg/kg/day |
Mean |
195.7 |
203.3 |
213.6 |
SD |
10.7 |
11.1 |
11.2 |
|
N |
10 |
10 |
10 |
|
Group: 3 300 mg/kg/day |
Mean |
193.9 |
201.3 |
216.7 |
SD |
11.7 |
12.6 |
11.0 |
|
N |
10 |
10 |
10 |
|
Group: 4 1000 mg/kg/day |
Mean |
188.9 |
202.8 |
209.3 |
SD |
5.8 |
9.2 |
9.0 |
|
N |
9 |
9 |
9 |
# [Statistically Analysed]
Table 3. Body Weights (g) - P Generation Females - Gestation - Group Mean Values
Sex: Female |
Body Weight (Day of Gestation) |
||||
Group |
0# |
7# |
14# |
20# |
|
Group: 1 Control 0 mg/kg/day |
Mean |
209.1 |
238.0 |
267.1 |
329.0 |
SD |
10.2 |
13.2 |
18.0 |
22.7 |
|
N |
10 |
10 |
10 |
10 |
|
Group: 2 100 mg/kg/day |
Mean |
217.1 |
241.1 |
270.3 |
329.2 |
SD |
11.1 |
11.6 |
12.8 |
18.4 |
|
N |
10 |
10 |
10 |
10 |
|
Group: 3 300 mg/kg/day |
Mean |
217.6 |
243.8 |
272.3 |
327.1 |
SD |
9.2 |
11.2 |
13.2 |
14.4 |
|
N |
10 |
10 |
10 |
10 |
|
Group: 4 1000 mg/kg/day |
Mean |
212.4 |
239.9 |
267.8 |
323.6 |
SD |
8.6 |
9.1 |
11.2 |
15.6 |
|
N |
9 |
9 |
9 |
9 |
# [Statistically Analysed]
Table 4. Body Weights (g) - P Generation Females - Lactation - Group Mean Values
Sex: Female |
Body Weight (Day of Lactation) |
||
Group |
1# |
4# |
|
Group: 1 Control 0 mg/kg/day |
Mean |
250.0 |
262.8 |
SD |
17.0 |
17.5 |
|
N |
10 |
10 |
|
Group: 2 100 mg/kg/day |
Mean |
253.5 |
270.3 |
SD |
14.1 |
15.9 |
|
N |
10 |
10 |
|
Group: 3 300 mg/kg/day |
Mean |
253.6 |
270.2 |
SD |
15.1 |
14.9 |
|
N |
10 |
10 |
|
Group: 4 1000 mg/kg/day |
Mean |
249.2 |
265.3 |
SD |
13.6 |
12.3 |
|
N |
9 |
9 |
# [Statistically Analysed]
Table 5. Body Weights (g) - F1 Generation Pups
Sex: Female |
Mean Pup BWt M+F (Day of Lactation) |
Weight Gain (Day of Lactation) |
||
Group |
1# |
4# |
1 to 4# |
|
Group: 1 Control 0 mg/kg/day |
Mean |
6.59 |
9.89 |
3.30 |
SD |
0.95 |
1.68 |
0.82 |
|
N |
10 |
10 |
10 |
|
Group: 2 100 mg/kg/day |
Mean |
6.61 |
10.14 |
3.53 |
SD |
0.33 |
0.57 |
0.32 |
|
N |
10 |
10 |
10 |
|
Group: 3 300 mg/kg/day |
Mean |
6.24 |
9.35 |
3.10 |
SD |
0.79 |
1.18 |
0.50 |
|
N |
10 |
10 |
10 |
|
Group: 4 1000 mg/kg/day |
Mean |
6.76 |
9.94 |
3.18 |
SD |
0.35 |
0.78 |
0.61 |
|
N |
9 |
9 |
9 |
Data are recorded and reported against dams, day of lactation is equivalent to day of age
# [Statistically Analysed]
Table 6. Fertility and Mating Data - P Generation - Group Mean Values
Sex: Both |
Group: 1 Control 0 mg/kg/day |
Group: 2 100 mg/kg/day |
Group: 3 300 mg/kg/day |
Group: 4 1000 mg/kg/day |
|
Number of Females Paired |
N+ve |
10 |
10 |
10 |
10 |
Number of Females Mated |
N+ve |
10 |
10 |
10 |
10 |
Number of Fertile Females |
N+ve |
10 |
10 |
10 |
10 |
Copulation Index Female %# |
Mean |
100.0 |
100.0 |
100.0 |
100.0 |
Female Fertility Index %# |
Mean |
100.0 |
100.0 |
100.0 |
100.0 |
Number of Males Paired |
N+ve |
10 |
10 |
10 |
10 |
Number of Males Mated |
N+ve |
10 |
10 |
10 |
10 |
Number of Fertile Males |
N+ve |
10 |
10 |
10 |
10 |
Copulation Index Male %# |
Mean |
100.0 |
100.0 |
100.0 |
100.0 |
Male Fertility Index %# |
Mean |
100.0 |
100.0 |
100.0 |
100.0 |
# [Statistically Analysed]
Table 7. Pregnancy and Litter Data - P Generation Females and Litters - Group Mean Values
Sex: Female |
Group: 1 Control 0 mg/kg/day |
Group: 2 100 mg/kg/day |
Group: 3 300 mg/kg/day |
Group: 4 1000 mg/kg/day |
|
Gestation Length (day)# |
Mean |
22.30 |
22.05 |
22.15 |
22.17 |
Gestation Index # |
% |
100.0 |
100.0 |
100.0 |
100.0 |
Total No of Implantation Scars |
Mean |
13.7 |
13.3 |
13.4 |
13.0 |
Total Pups Born# |
Mean |
13.0 |
12.3 |
12.6 |
11.8 |
Post Implantation Loss %# |
Mean |
5.3 |
7.4 |
7.0 |
8.9 |
Live Pups on Day 0 |
Mean |
13.0 |
12.3 |
12.6 |
11.8 |
Live Pups on Day 1 |
Mean |
12.9 |
12.2 |
12.4 |
11.8 |
Live Pups Day 4 (Pre Cull) |
Mean |
12.9 |
12.2 |
12.4 |
11.7 |
Live Birth Index (%)# |
Mean |
100.00 |
100.00 |
100.00 |
100.00 |
Viability Index 1 (%)# |
Mean |
99.23 |
99.00 |
98.50 |
99.15 |
Cumulative Survival Index % # |
Mean |
99.23 |
99.00 |
98.50 |
99.15 |
% Males# |
Mean |
56.57 |
42.85 |
54.10 |
51.24 |
# [Statistically Analysed]
Table 8. Litter Necropsy Findings - F1 Generation - Summary
Sex : Females |
Group: 1 Control 0 mg/kg/day |
Group: 2 100 mg/kg/day |
Group: 3 300 mg/kg/day |
Group: 4 1000 mg/kg/day |
Total number of litters |
10 |
10 |
10 |
10 |
|
|
|
|
|
Number of pups |
|
|
|
|
|
|
|
|
|
Born |
130 |
123 |
126 |
119 |
Found dead/killed prematurely |
0 |
0 |
1 |
13 |
Missing (presumed cannibalised) |
1 |
1 |
1 |
1 |
Abnormalities |
0 |
0 |
0 |
1 |
Left kidney pelvic dilation severe left uterer distended severe |
0 |
0 |
0 |
1 |
Table 9. Organ Weights (g) - P Generation Males - Group Mean Values
Sex: Male |
Dead Body Weight |
Absolute Liver Weight |
Adjusted Liver Weight |
Liver % Body Weight |
Absolute Testes Weight |
Adjusted Testes wt |
Testes % Body Weight |
Absolute Epididymides Weight |
Adjusted Epididymides wt |
Epididymides % Body Weight |
Absolute Thyroids Weight |
Adjusted Thyroids wt |
Thyroids % Body Weight |
||||
Group |
# |
# |
# |
|
# |
# |
|
# |
# |
|
# |
# |
|
||||
Group: 1 Control 0 mg/kg/day |
Mean |
401.79 |
13.744 |
13.33 |
3.42 |
3.722 |
3.680 |
0.928 |
1.352 |
1.334 |
0.337 |
0.0217 |
0.0210 |
0.0054 |
|||
SD |
18.57 |
0.881 |
|
0.20 |
0.428 |
|
0.111 |
0.146 |
|
0.037 |
0.0037 |
|
0.0010 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 2 100 mg/kg/day |
Mean |
413.45 |
14.572 |
13.66 |
3.52 |
3.527 |
3.436 |
0.854 |
1.304 |
1.265 |
0.315 |
0.0224 |
0.0210 |
0.0054 |
|||
SD |
24.52 |
1.010 |
|
0.14 |
0.299 |
|
0.071 |
0.121 |
|
0.022 |
0.0032 |
|
0.0007 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 3 300 mg/kg/day |
Mean |
385.64 |
14.826 |
15.09 |
dd2 |
3.83 |
3.470 |
3.497 |
0.903 |
1.272 |
1.283 |
0.332 |
0.0222 |
0.0220 |
0.0058 |
||
SD |
32.22 |
2.185 |
|
0.28 |
0.287 |
|
0.079 |
0.129 |
|
0.040 |
0.0033 |
|
0.0008 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 4 1000 mg/kg/day |
Mean |
367.01 |
d1 |
15.431 |
d1 |
16.49 |
dd2 |
4.21 |
3.555 |
3.661 |
0.971 |
1.253 |
1.298 |
0.342 |
0.0222 |
0.0230 |
0.0060 |
SD |
28.81 |
1.129 |
|
0.20 |
0.299 |
|
0.078 |
0.151 |
|
0.035 |
0.0041 |
|
0.0009 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
# [Statistically Analysed]
1 [d - Test: Dunnett 2 Sided p < 0.05] 2 [dd - Test: Dunnett 2 Sided p < 0.01]
Table 10. Organ Weights (g) - P Generation Females - Group Mean Values
Sex: Female |
Dead Body Weight |
Absolute Liver Weight |
Adjusted Liver Weight |
Liver % Body Weight |
Absolute Thyroids wt |
Adjusted Thyroids wt |
Thyroids % Body Weight |
||||
Group |
# |
# |
# |
|
# |
# |
|
||||
Group: 1 Control 0 mg/kg/day |
Mean |
261.23 |
11.405 |
11.60 |
4.37 |
0.0157 |
0.0159 |
0.0060 |
|||
SD |
18.65 |
1.266 |
|
0.36 |
0.0033 |
|
0.0011 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 2 100 mg/kg/day |
Mean |
267.91 |
11.783 |
11.64 |
4.39 |
0.0187 |
0.0186 |
0.0070 |
|||
SD |
15.92 |
1.108 |
|
0.25 |
0.0031 |
|
0.0010 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 3 300 mg/kg/day |
Mean |
268.53 |
12.153 |
11.98 |
4.52 |
0.0194 |
d2 |
0.0192 |
0.0072 |
||
SD |
11.51 |
1.113 |
|
0.31 |
0.0033 |
|
0.0013 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 4 1000 mg/kg/day |
Mean |
262.23 |
12.979 |
dd1 |
13.12 |
dd1 |
4.95 |
0.0181 |
0.0183 |
0.0069 |
|
SD |
12.13 |
0.780 |
|
0.25 |
0.0032 |
|
0.0014 |
||||
N |
9 |
9 |
9 |
9 |
9 |
9 |
9 |
||||
# [Statistically Analysed]
1 [dd - Test: Dunnett 2 Sided p < 0.01] 2 [d - Test: Dunnett 2 Sided p < 0.05]
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 015
- Report date:
- 2015
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guidelines for the Testing of Chemicals, No. 421
- Version / remarks:
- Adopted 22nd January 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: OPPTS 870.3550 Reproduction/Developmental Toxicity Screening Test
- Version / remarks:
- July 2000
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- rac-(1R,4S,4aR,8R,8aS)-9-(dichloromethylidene)-8-hydroxyoctahydro-1,4-methanonaphthalen-5(1H)-one
- EC Number:
- 941-628-3
- Cas Number:
- 1263184-87-7
- Molecular formula:
- C12H14Cl2O2
- IUPAC Name:
- rac-(1R,4S,4aR,8R,8aS)-9-(dichloromethylidene)-8-hydroxyoctahydro-1,4-methanonaphthalen-5(1H)-one
- Test material form:
- solid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:WI(Han)
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: (P) 8 to 9 weeks
- Weight at study initiation: (P) Males: 269 to 325 g; Females: 175 to 214 g
- Fasting period before study: No
- Housing: Animals were housed in groups of five, by sex, until pairing and for males post-pairing. For pairing, one male and one female from the same group were housed together in grid-floor cages suspended over paper-lined trays. On confirmation of mating, the males were returned to the group cages and the mated females were housed individually and subsequently with their litter, in solid floor cages with bedding material provided.
- Diet: pelleted rodent diet, ad libitum
- Water: Tap water, ad libitum
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 to 22
- Humidity (%): 45 to 63
- Air changes (per hr): Not specified
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES:
14 May 2014 to 14 Oct 2014
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- CMC (carboxymethyl cellulose)
- Remarks:
- 1% (w/v)
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test item was formulated at approximately weekly intervals (within the period of known stability), for each group separately, as a suspension in 1 % (w/v) aqueous carboxymethylcellulose. A weighed quantity of test item was added to a beaker and vehicle was gradually added whilst stirring. The suspension was removed from the stirrer and made up to final volume/weight with more vehicle and mixed with a laboratory homogeniser. For the formulations prepared for use on the first dosing occasion only, solid black flecks were visible after homogenisation and therefore the formulations were placed in an ultrasonic bath for up to 114 minutes, to ensure complete dispersion and homogeneity. After preparation, all formulations were dispensed into daily aliquots which were stored refrigerated. Formulations were stirred from at least 15 minutes before the start of dosing until completion of dosing to ensure thorough re-suspension and homogeneity.
VEHICLE
- Concentration in vehicle: 0 (control), 10, 30 and 100 mg/mL, corresponds to 0, 100, 300 and 1000 mg/kg bw/day test substance in dose formulation
- Amount of vehicle: 10 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentrations of the test substance in formulations used on the first and last days of dosing have been determined using a validated method of analysis. The concentrations and homogeneity of the test substance in the formulations used on the first dosing occasion were determined from the analysis of triplicate samples from the top, middle and bottom of each formulation. The achieved concentrations of the test substance in the formulations used on the last day of dosing were determined from the analysis of triplicate samples from the middle of each formulation.
Samples from vehicle used to dose control animals on these occasions were analysed to confirm the absence of test substance. The formulations were considered to have been accurately prepared and homogeneous (where assessed) if the measured concentrations of the test substance were within ± 10% of their nominal values with coefficients of variation no greater than 5%. - Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: up to 14 days
- Proof of pregnancy: sperm in vaginal smear referred to as Day 0 of pregnancy
- After 14 days of unsuccessful pairing replacement of first male by another male with proven fertility.
- Further matings after two unsuccessful attempts: no
- After successful mating each pregnant female was caged individually - Duration of treatment / exposure:
- Males were dosed once daily for 14 days before and during pairing and until the day before necropsy.
Females were dosed once daily for 14 days before pairing, during pairing and until Day 3 of lactation. Animals that were in midparturition at the time of dosing were not dosed on that day. - Frequency of treatment:
- Once daily
- Duration of test:
- Males were dosed once daily for 14 days before and during pairing and until the day before necropsy.
Females were dosed once daily for 14 days before pairing, during pairing and until Day 3 of lactation. Animals that were in midparturition at the time of dosing were not dosed on that day.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Remarks:
- Group 2
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Remarks:
- Group 3
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- Group 4
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels were selected by the Sponsor after examining existing toxicity data from a 28 day toxicity study.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS:
- Time schedule: daily for clinical signs of toxicity or changes in behaviour and appearance and each animal. Furthermore, twice daily for mortality and morbidity.
DETAILED CLINICAL OBSERVATIONS:
- Time schedule: Once each week
BODY WEIGHT:
- Time schedule for examinations: Male body weights were recorded on the first day of dosing and at weekly intervals throughout the study. Female body weights were recorded on the first day of dosing and then at weekly intervals until the day of mating. Females were also weighed on Days 0, 7, 14 and 20 of gestation and on Days 0 (where required for dose volume calculations), 1 and 4 of lactation.
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/animal/day: Yes
POST-MORTEM EXAMINATIONS:
- Male animals: All surviving animals were sacrificed after the females had littered and been necropsied
- Maternal animals: All surviving animals were sacrificed on Day 4 of lactation
- Organs examined: Gross necropsy consisted of external and internal examinations including the thoracic, and abdominal viscera. For females, the uterus was examined and the number of implantation scars recorded on Day 4 of lactation.
- Histopathology and organ weights: The tissues indicated in Table 1 in ‘Any other information on materials and methods incl. tables’ were prepared for microscopic examination and weighed, respectively
OTHER:
The females were allowed to rear their offspring to Day 4 of lactation. Abnormalities of nesting or nursing behaviour were recorded. - Ovaries and uterine content:
- The uterine content was examined after termination:
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: No
- Number of implantations: Yes
- Number of early resorptions: No
- Number of late resorptions: No - Fetal examinations:
- - External examinations: Yes
- Soft tissue examinations: Yes
- Skeletal examinations: No
- Head examinations: No - Statistics:
- Data were processed to give group mean values and standard deviations, where appropriate. Where the data allowed, the following methods were used for statistical analysis comparing Groups 2, 3 and 4 against Group 1.
General Approach: All statistical tests were two-sided with minimum significance levels of 5% and 1%. Non-parametric statistics were not routinely conducted. When used, Dunnett’s test was conducted regardless of the outcome of the analysis of variance (ANOVA) or analysis of covariance (ANCOVA). After examining for any outliers, if the variances were clearly heterogeneous, transformations were used in an attempt to stabilise the variances.
For Quantitative Data: Body weight, food intake, cumulative body weight gain from the start of dosing (throughout gestation and lactation), pup body weights, cumulative pup body weight gain, litter size, gestation length and total litter weight were analysed using ANOVA. Parental organ weights were analysed using ANOVA for the absolute weights and by analysis of covariance (ANCOVA) using terminal kill body weight as covariate.
For Percentages: Pup survival, pup sex ratios and litter based mean percentages were analysed using a parametric ANOVA, following a double arcsine transformation.
Dunnett’s test: For all of the parameters evaluated initially by ANOVA or ANCOVA, Dunnett’s test was used to compare the control and treated groups, based on the error mean square in the ANOVA or ANCOVA. The Dunnett’s test was performed for all continuous data parameters, regardless of whether the initial ANOVA or ANCOVA was statistically significant, and statistical flags are presented in the tables of results in the final report. - Indices:
- See Table 2 in 'Any other information on materials and methods incl. tables'.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no test item-related clinical observations.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One female animal, administered 1000 mg/kg/day, was killed on Day 0 of lactation due to poor clinical condition within 102 minutes of dosing. Littering had been completed successfully and 13 live pups born. However, observations post dosing included decreased activity, prostrate posture and slow breathing indicative of a possible mis-dose although there were no macroscopic necropsy findings to confirm this. This death was an isolated incidence and, in the absence of other deaths or clinical signs of toxicity at 1000 mg/kg/day in this study or in a 28-day toxicity study, was considered to be incidental and not related to treatment with the test item.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Throughout the dosing period, males given 1000 mg/kg/day had reduced body weight gains (p<0.01) compared with Controls (-29 %). Males given 300 mg/kg/day had lower body weight gains (-9 %) throughout the dosing period compared with Controls, although the difference was not statistically significant. There was no effect on body weight or body weight gains for males at 100 mg/kg/day or for females during pre-pairing, gestation or lactation, at any dose level.
See Tables 1 to 4 in ‘Any other information on results incl. tables’. - Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- There were statistically significant increases in liver weight adjusted for body weight (p<0.01) in the males administered 300 mg/kg/day (+13 %) and in males and females administered 1000 mg/kg/day (+24 % and +13 %, respectively), compared with the Controls.
There was no effect of the test substanceon testes, epididymides or thyroid weights.
See Tables 9 and 10 in ‘Any other information on results incl. tables’. - Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The spectrum of all macroscopic findings was consistent with changes encountered in rats of this age kept under laboratory conditions and there was no evidence of any treatment-related effects.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment-related microscopic changes were found in the liver of males and females and in the thyroid of males. These changes are described below. The spectrum of all other microscopic findings was consistent with changes encountered in rats of this age kept under laboratory conditions and none was considered to be treatment-related.
Liver: Hepatocellular hypertrophy (minimal) was present in all males and 2/10 females given 1000 mg/kg/day and in 2/10 males given 300 mg/kg/day. The incidence of the treatment related change was dose-related in males and accounted for the observed dose-related increases in liver weight in both sexes.
Thyroids: There was an increased incidence of thyroid follicular hypertrophy (minimal) in males given 300 mg/kg/day or 1000 mg/kg/day when compared with males from the Control group. This increased incidence was considered to be treatment-related. Although the incidence of follicular cell hypertrophy in males given 100 mg/kg/day was greater than that found in the concurrent Controls, the finding was considered to be within the spectrum of change encountered in male rats of this strain kept under laboratory conditions and therefore incidental to treatment. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not examined
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- There was no effect on the number of implantation scars or the incidence of postimplantation loss.
See Table 7 in ‘Any other information on results incl. tables’. - Total litter losses by resorption:
- no effects observed
- Description (incidence and severity):
- There were no total litter losses.
- Early or late resorptions:
- not examined
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- See Table 7 in ‘Any other information on results incl. tables’.
- Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- See Table 7 in ‘Any other information on results incl. tables’.
- Other effects:
- not examined
Effect levels (maternal animals)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Systemic toxicity (males)
- Effect level:
- 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- Dose descriptor:
- NOAEL
- Remarks:
- Systemic toxicity (females)
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- histopathology: non-neoplastic
- organ weights and organ / body weight ratios
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Reproductive toxicity
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Maternal abnormalities
- Key result
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- See Table 5 in ‘Any other information on results incl. tables’.
- Reduction in number of live offspring:
- no effects observed
- Description (incidence and severity):
- See Table 8 in ‘Any other information on results incl. tables’.
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- not examined
- Visceral malformations:
- no effects observed
- Other effects:
- not examined
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Any other information on results incl. tables
Formulation analysis
Test item formulations from the first preparation occasion and those used on the last day of dosing were considered to have been accurately prepared and homogeneous (where assessed) since the measured concentrations of the test substance were within 5 % of their nominal values with coefficients of variation no greater than 1.3 % which fulfilled the acceptance criteria (± 10 % and ≤ 5 % for accuracy and homogeneity, respectively).
No test substance was detected in vehicle used to dose Control animals.
Table 1. Body Weights (g) - P Generation Males - Group Mean Values
Sex: Male |
Body Weight (Week Number) |
|||||||
Group |
0# |
1# |
2# |
3# |
4# |
5# |
6# |
|
Group: 1 Control 0 mg/kg/day |
Mean |
294.0 |
320.0 |
340.7 |
353.6 |
365.0 |
380.0 |
392.3 |
SD |
14.0 |
16.1 |
17.9 |
16.6 |
18.9 |
19.6 |
16.6 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Group: 2 100 mg/kg/day |
Mean |
295.6 |
324.9 |
348.7 |
354.8 |
377.8 |
390.9 |
402.5 |
SD |
17.8 |
20.6 |
21.7 |
16.2 |
22.8 |
21.0 |
22.7 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Group: 3 300 mg/kg/day |
Mean |
288.4 |
308.6 |
328.6 |
341.3 |
352.6 |
368.4 |
377.9 |
SD |
18.5 |
21.6 |
25.9 |
26.3 |
24.6 |
31.1 |
28.6 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Group: 4 1000 mg/kg/day |
Mean |
291.5 |
301.1 |
321.4 |
335.1 |
345.8 |
352.0 d1 |
361.5 d1 |
SD |
15.1 |
23.5 |
23.8 |
24.1 |
25.4 |
25.4 |
26.0 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
# [Statistically Analysed]
1 [d - Test: Dunnett 2 Sided p < 0.05]
Table 2. Body Weights (g) - P Generation Females - Pre-Pairing - Group Mean Values
Sex: Female |
Body Weight (Week Number) |
|||
Group |
0# |
1# |
2# |
|
Group: 1 Control 0 mg/kg/day |
Mean |
189.4 |
198.2 |
209.0 |
SD |
7.1 |
7.1 |
8.5 |
|
N |
10 |
10 |
10 |
|
Group: 2 100 mg/kg/day |
Mean |
195.7 |
203.3 |
213.6 |
SD |
10.7 |
11.1 |
11.2 |
|
N |
10 |
10 |
10 |
|
Group: 3 300 mg/kg/day |
Mean |
193.9 |
201.3 |
216.7 |
SD |
11.7 |
12.6 |
11.0 |
|
N |
10 |
10 |
10 |
|
Group: 4 1000 mg/kg/day |
Mean |
188.9 |
202.8 |
209.3 |
SD |
5.8 |
9.2 |
9.0 |
|
N |
9 |
9 |
9 |
# [Statistically Analysed]
Table 3. Body Weights (g) - P Generation Females - Gestation - Group Mean Values
Sex: Female |
Body Weight (Day of Gestation) |
||||
Group |
0# |
7# |
14# |
20# |
|
Group: 1 Control 0 mg/kg/day |
Mean |
209.1 |
238.0 |
267.1 |
329.0 |
SD |
10.2 |
13.2 |
18.0 |
22.7 |
|
N |
10 |
10 |
10 |
10 |
|
Group: 2 100 mg/kg/day |
Mean |
217.1 |
241.1 |
270.3 |
329.2 |
SD |
11.1 |
11.6 |
12.8 |
18.4 |
|
N |
10 |
10 |
10 |
10 |
|
Group: 3 300 mg/kg/day |
Mean |
217.6 |
243.8 |
272.3 |
327.1 |
SD |
9.2 |
11.2 |
13.2 |
14.4 |
|
N |
10 |
10 |
10 |
10 |
|
Group: 4 1000 mg/kg/day |
Mean |
212.4 |
239.9 |
267.8 |
323.6 |
SD |
8.6 |
9.1 |
11.2 |
15.6 |
|
N |
9 |
9 |
9 |
9 |
# [Statistically Analysed]
Table 4. Body Weights (g) - P Generation Females - Lactation - Group Mean Values
Sex: Female |
Body Weight (Day of Lactation) |
||
Group |
1# |
4# |
|
Group: 1 Control 0 mg/kg/day |
Mean |
250.0 |
262.8 |
SD |
17.0 |
17.5 |
|
N |
10 |
10 |
|
Group: 2 100 mg/kg/day |
Mean |
253.5 |
270.3 |
SD |
14.1 |
15.9 |
|
N |
10 |
10 |
|
Group: 3 300 mg/kg/day |
Mean |
253.6 |
270.2 |
SD |
15.1 |
14.9 |
|
N |
10 |
10 |
|
Group: 4 1000 mg/kg/day |
Mean |
249.2 |
265.3 |
SD |
13.6 |
12.3 |
|
N |
9 |
9 |
# [Statistically Analysed]
Table 5. Body Weights (g) - F1 Generation Pups
Sex: Female |
Mean Pup BWt M+F (Day of Lactation) |
Weight Gain (Day of Lactation) |
||
Group |
1# |
4# |
1 to 4# |
|
Group: 1 Control 0 mg/kg/day |
Mean |
6.59 |
9.89 |
3.30 |
SD |
0.95 |
1.68 |
0.82 |
|
N |
10 |
10 |
10 |
|
Group: 2 100 mg/kg/day |
Mean |
6.61 |
10.14 |
3.53 |
SD |
0.33 |
0.57 |
0.32 |
|
N |
10 |
10 |
10 |
|
Group: 3 300 mg/kg/day |
Mean |
6.24 |
9.35 |
3.10 |
SD |
0.79 |
1.18 |
0.50 |
|
N |
10 |
10 |
10 |
|
Group: 4 1000 mg/kg/day |
Mean |
6.76 |
9.94 |
3.18 |
SD |
0.35 |
0.78 |
0.61 |
|
N |
9 |
9 |
9 |
Data are recorded and reported against dams, day of lactation is equivalent to day of age
# [Statistically Analysed]
Table 6. Fertility and Mating Data - P Generation - Group Mean Values
Sex: Both |
Group: 1 Control 0 mg/kg/day |
Group: 2 100 mg/kg/day |
Group: 3 300 mg/kg/day |
Group: 4 1000 mg/kg/day |
|
Number of Females Paired |
N+ve |
10 |
10 |
10 |
10 |
Number of Females Mated |
N+ve |
10 |
10 |
10 |
10 |
Number of Fertile Females |
N+ve |
10 |
10 |
10 |
10 |
Copulation Index Female %# |
Mean |
100.0 |
100.0 |
100.0 |
100.0 |
Female Fertility Index %# |
Mean |
100.0 |
100.0 |
100.0 |
100.0 |
Number of Males Paired |
N+ve |
10 |
10 |
10 |
10 |
Number of Males Mated |
N+ve |
10 |
10 |
10 |
10 |
Number of Fertile Males |
N+ve |
10 |
10 |
10 |
10 |
Copulation Index Male %# |
Mean |
100.0 |
100.0 |
100.0 |
100.0 |
Male Fertility Index %# |
Mean |
100.0 |
100.0 |
100.0 |
100.0 |
# [Statistically Analysed]
Table 7. Pregnancy and Litter Data - P Generation Females and Litters - Group Mean Values
Sex: Female |
Group: 1 Control 0 mg/kg/day |
Group: 2 100 mg/kg/day |
Group: 3 300 mg/kg/day |
Group: 4 1000 mg/kg/day |
|
Gestation Length (day)# |
Mean |
22.30 |
22.05 |
22.15 |
22.17 |
Gestation Index # |
% |
100.0 |
100.0 |
100.0 |
100.0 |
Total No of Implantation Scars |
Mean |
13.7 |
13.3 |
13.4 |
13.0 |
Total Pups Born# |
Mean |
13.0 |
12.3 |
12.6 |
11.8 |
Post Implantation Loss %# |
Mean |
5.3 |
7.4 |
7.0 |
8.9 |
Live Pups on Day 0 |
Mean |
13.0 |
12.3 |
12.6 |
11.8 |
Live Pups on Day 1 |
Mean |
12.9 |
12.2 |
12.4 |
11.8 |
Live Pups Day 4 (Pre Cull) |
Mean |
12.9 |
12.2 |
12.4 |
11.7 |
Live Birth Index (%)# |
Mean |
100.00 |
100.00 |
100.00 |
100.00 |
Viability Index 1 (%)# |
Mean |
99.23 |
99.00 |
98.50 |
99.15 |
Cumulative Survival Index % # |
Mean |
99.23 |
99.00 |
98.50 |
99.15 |
% Males# |
Mean |
56.57 |
42.85 |
54.10 |
51.24 |
# [Statistically Analysed]
Table 8. Litter Necropsy Findings - F1 Generation - Summary
Sex : Females |
Group: 1 Control 0 mg/kg/day |
Group: 2 100 mg/kg/day |
Group: 3 300 mg/kg/day |
Group: 4 1000 mg/kg/day |
Total number of litters |
10 |
10 |
10 |
10 |
|
|
|
|
|
Number of pups |
|
|
|
|
|
|
|
|
|
Born |
130 |
123 |
126 |
119 |
Found dead/killed prematurely |
0 |
0 |
1 |
13 |
Missing (presumed cannibalised) |
1 |
1 |
1 |
1 |
Abnormalities |
0 |
0 |
0 |
1 |
Left kidney pelvic dilation severe left uterer distended severe |
0 |
0 |
0 |
1 |
Table 9. Organ Weights (g) - P Generation Males - Group Mean Values
Sex: Male |
Dead Body Weight |
Absolute Liver Weight |
Adjusted Liver Weight |
Liver % Body Weight |
Absolute Testes Weight |
Adjusted Testes wt |
Testes % Body Weight |
Absolute Epididymides Weight |
Adjusted Epididymides wt |
Epididymides % Body Weight |
Absolute Thyroids Weight |
Adjusted Thyroids wt |
Thyroids % Body Weight |
||||
Group |
# |
# |
# |
|
# |
# |
|
# |
# |
|
# |
# |
|
||||
Group: 1 Control 0 mg/kg/day |
Mean |
401.79 |
13.744 |
13.33 |
3.42 |
3.722 |
3.680 |
0.928 |
1.352 |
1.334 |
0.337 |
0.0217 |
0.0210 |
0.0054 |
|||
SD |
18.57 |
0.881 |
|
0.20 |
0.428 |
|
0.111 |
0.146 |
|
0.037 |
0.0037 |
|
0.0010 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 2 100 mg/kg/day |
Mean |
413.45 |
14.572 |
13.66 |
3.52 |
3.527 |
3.436 |
0.854 |
1.304 |
1.265 |
0.315 |
0.0224 |
0.0210 |
0.0054 |
|||
SD |
24.52 |
1.010 |
|
0.14 |
0.299 |
|
0.071 |
0.121 |
|
0.022 |
0.0032 |
|
0.0007 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 3 300 mg/kg/day |
Mean |
385.64 |
14.826 |
15.09 |
dd2 |
3.83 |
3.470 |
3.497 |
0.903 |
1.272 |
1.283 |
0.332 |
0.0222 |
0.0220 |
0.0058 |
||
SD |
32.22 |
2.185 |
|
0.28 |
0.287 |
|
0.079 |
0.129 |
|
0.040 |
0.0033 |
|
0.0008 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 4 1000 mg/kg/day |
Mean |
367.01 |
d1 |
15.431 |
d1 |
16.49 |
dd2 |
4.21 |
3.555 |
3.661 |
0.971 |
1.253 |
1.298 |
0.342 |
0.0222 |
0.0230 |
0.0060 |
SD |
28.81 |
1.129 |
|
0.20 |
0.299 |
|
0.078 |
0.151 |
|
0.035 |
0.0041 |
|
0.0009 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
# [Statistically Analysed]
1 [d - Test: Dunnett 2 Sided p < 0.05] 2 [dd - Test: Dunnett 2 Sided p < 0.01]
Table 10. Organ Weights (g) - P Generation Females - Group Mean Values
Sex: Female |
Dead Body Weight |
Absolute Liver Weight |
Adjusted Liver Weight |
Liver % Body Weight |
Absolute Thyroids wt |
Adjusted Thyroids wt |
Thyroids % Body Weight |
||||
Group |
# |
# |
# |
|
# |
# |
|
||||
Group: 1 Control 0 mg/kg/day |
Mean |
261.23 |
11.405 |
11.60 |
4.37 |
0.0157 |
0.0159 |
0.0060 |
|||
SD |
18.65 |
1.266 |
|
0.36 |
0.0033 |
|
0.0011 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 2 100 mg/kg/day |
Mean |
267.91 |
11.783 |
11.64 |
4.39 |
0.0187 |
0.0186 |
0.0070 |
|||
SD |
15.92 |
1.108 |
|
0.25 |
0.0031 |
|
0.0010 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 3 300 mg/kg/day |
Mean |
268.53 |
12.153 |
11.98 |
4.52 |
0.0194 |
d2 |
0.0192 |
0.0072 |
||
SD |
11.51 |
1.113 |
|
0.31 |
0.0033 |
|
0.0013 |
||||
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
||||
Group: 4 1000 mg/kg/day |
Mean |
262.23 |
12.979 |
dd1 |
13.12 |
dd1 |
4.95 |
0.0181 |
0.0183 |
0.0069 |
|
SD |
12.13 |
0.780 |
|
0.25 |
0.0032 |
|
0.0014 |
||||
N |
9 |
9 |
9 |
9 |
9 |
9 |
9 |
||||
# [Statistically Analysed]
1 [dd - Test: Dunnett 2 Sided p < 0.01] 2 [d - Test: Dunnett 2 Sided p < 0.05]
Applicant's summary and conclusion
- Conclusions:
- In this GLP compliant OECD 421 study, a reproduction/ developmental toxicity screening was performed on male and female Crl:WI(Han) mice. The following NOAELs were found:
- Systemic toxicity: 100 mg/kg bw/day based on reduced body weight, increased liver weights and minimal hepatocellular hypertrophy in males.
- Reproductive toxicity: > 1000 mg/kg bw/day
- Developmental toxicity: > 1000 mg/kg bw/day - Executive summary:
In this GLP compliant OECD 421 study, a reproduction/ developmental toxicity screening was performed. Forty male and 40 female rats of the Crl:WI(Han) strain were allocated to the study. Groups of 10 males and 10 females were dosed with 0 (vehicle), 100, 300 or 1000 mg/kg/day test substance, once daily, by oral gavage at a dose volume of 10 mL/kg body weight using 1% aqueous carboxymethylcellulose as vehicle. Males were dosed for 14 days before and during pairing and until the day before necropsy (47 days) and the females were dosed for 14 days before pairing, during pairing and then until Day 3 of lactation (approximately 42 days). All animals were examined for effects on general condition, body weight and food intake. During the pairing period vaginal smears were taken daily until sperm were found in the smear. The females were allowed to litter and rear their offspring to Day 4 of age. A macroscopic necropsy was performed on all parental animals and F1 generation pups. For the parental males and females a selection of organs were weighed, fixed and examined microscopically.
There were no deaths considered to be related to treatment with the test item and no test-item related clinical signs. Throughout the dosing period, males given 300 mg/kg/day or 1000 mg/kg/day showed reduced body weight gain, compared with Controls. There was no effect on body weight or body weight gain for females at any dose level or for males given 100 mg/kg/day. There was no effect on food intake for males or females at any dose level. Fertility and mating performance were unaffected by treatment with the test substance and there were no effects on pregnancy parameters. Males given 300 mg/kg/day and both sexes given 1000 mg/kg/day showed increased liver weights adjusted for body weight. Minimal hepatocellular hypertrophy was noted in males given 300 mg/kg/day and in both sexes given 1000 mg/kg/day. Minimal thyroid follicular hypertrophy was also seen in males given 300 or 1000 mg/kg/day. There was no effect of maternal treatment with the test substance on pup body weights to Day 4 of age. Pup survival was similar across all groups including the Controls.
In conclusion, the test substance administered once daily by oral gavage to male and female rats at doses of 0, 100, 300 or 1000 mg/kg/day was well tolerated at all dose levels. The No Observed Adverse Effect Level (NOAEL) for male and female reproductive performance was 1000 mg/kg/day. The NOAEL for parental toxicity was 100 mg/kg/day. Reduced body weight and thyroid follicular hypertrophy were observed at the higher dose levels in males only. Increased liver weight in association with minimal hepatocellular hypertrophy was observed at 300 (males only) and 1000 mg/kg/day, in both sexes with males being more severely affected than females. The NOAEL for toxicity to the offspring was 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.